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upper dermis in close proximity to Merkel cells, the neu- Sculpting Heart Valves
roendocrine cells of the skin that participate in tactile with NFATc and VEGFsensation. It has been suggested that perhaps the
unique interactions and cell-cell contacts between the
bulge and the arrector pili muscle could be an important
factor in maintaining bulge cells in their undifferentiated Heart valves are of vital importance for our moment-
state (Akiyama et al., 1995). to-moment existence, but how they form remains a
Within the niche itself, the hair follicle bulge region is mystery. In this issue of Cell, Chang et al. reveal a
also cohabited by cells derived from two neural crest novel role for calcineurin, NFATs, and VEGF in valve
lineages, the melanocyte and the Merkel cell. Melano- formation (Chang et al., 2004). Dynamic changes in
cytes are involved in the pigmentation of the hair shaft NFAT/VEGF expression in regional myocardial and en-
in the mouse and both hair shaft and epidermis in the docardial fields and developmental windows orches-
human and reside within the niche (Nishimura et al., trate this complex process.
2002). The function of resident Merkel cells within the
hair follicle stem cell niche, however, is entirely un- In contrast to primitive organisms, the heart in mammals
known. Since these cells have no connection with peri- contains four chambers. Valve leaflets between the up-
follicular sensory nerve endings, it was suggested some per and lower heart chambers and the large vessels are
ten years ago that perhaps the Merkel cells serve a stem critical for the heart to pump the blood to the various
cell maintenance function rather than the tactile receptor parts of the body. In the embryonic heart, a complex
role served by Merkel cells in the skin (Narisawa et al., interplay of precisely regulated signals is required so
1994). With the recent discovery of pluripotent neural that each valve develops at a critical stage and a precise
crest stem cells within the rat hair follicle (Sieber-Blum location. Because of this complexity, the process often
and Grim, 2004), it may be time to look inward to neigh- derails, resulting in valve defects that affect up to one
boring cells in the niche for the answers to questions in 100 newborns and represent the most common birth
raised by Blanpain et al. (2004), such as, “What keeps defects in humans.
a stem cell a stem cell?” Soon after the primordial heart forms as an inner endo-
Perhaps uncovering the secrets of the hair follicle thelial (endocardial) tube into an inner endothelial tube
will be facilitated by going back to our roots, when the (endocardium) with a surrounding muscular layer (myo-
difference between neural and epidermal cell fates was cardium), endocardial cushions form from expansion
a simple choice between neighboring cells. The study of the extracellular matrix (cardiac jelly) in the region
of this uniquely mammalian stem cell niche provides us between the upper (atrial) and lower (ventricular) heart
with a developmental system rivaling the Drosophila chambers (Figure 1). At embryonic day 9 (E9), endocar-
germ cell niche (Fuchs et al., 2004) in which to delve dial cells at the atrioventricular canal undergo an endo-
deeply into the mysteries of adult stem cell biology in cardial-to-mesenchymal transformation (EMT) during a
the context of the skin and hair follicle. brief developmental period (E9–E10). In response to sig-
nals released from the underlying myocardium, these
endocardial cells separate from the endocardium andAngela M. Christiano
transform into mesenchymal cells, invading the cardiacDepartments of Dermatology
jelly. After expansion, these cells further differentiateand Genetics and Development
and reshape the rudimentary valves into slender leaflets.Columbia University
Multiple transcription and growth factors, adhesion mol-College of Physicians and Surgeons
ecules, and proteases have been implicated in valveNew York, New York 10032
formation (Schroeder et al., 2003), but much of the pre-
Selected Reading cise combinatorial code regulating this process remains
to be elucidated.
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Figure 1. Between E9 and E10, Endocardial Cells Undergo Endocardial-to-Mesenchymal Transformation
VEGF dose-dependently controls endocardial-to-mesenchymal transformation (EMT) in the AVC field: minimal levels at E9.0 are required for
EMT, while high levels at E10.5 terminate EMT. By preventing VEGF expression from reaching excessive levels at E9, NFATc2, c3, and c4 in
the myocardium allow EMT to proceed. VEGF in the adjacent regions outside the AVC field might suppress EMT. At E11, NFATc1 in the
endocardium controls valve maturation, but the signals remain to be determined. EC, endocardium; My, myocardium; AVC, atrioventricular
canal; MC, mesenchymal cells.
VEGF binds its receptors, Flt1, Flk1, and the neuropilins, after in the endocardium, determine valve initiation and
maturation (Figure 1). At E9.0–9.5, CnB activates NFATc2,all expressed in the endocardium. Even more striking is
that VEGF, while being necessary for initial EMT, subse- c3, and c4 in the myocardium and, by regulating the
expression of VEGF, allows the overlying endocardiumquently terminates this process (Figure 1). This dual
activity of VEGF seems to be strictly dose dependent to undergo EMT. But by 10.5, CnB activates NFATc1 in
the endocardium, where it provides signals for valveand dynamically controlled in narrowly defined temporal
windows and regional fields. Around the onset of EMT elongation.
Chang et al. deduce their model from several linesat E9.0, VEGF levels are detectable in the myocardium
in and outside the atrioventricular canal (Dor et al., 2001, of evidence (Chang et al., 2004). A role of calcineurin
signaling in the myocardium was supported by findings2003; Miquerol et al., 2000). Loss of a single VEGF allele
or the VEGF164 isoform results in underdeveloped en- that EMT was inhibited by treatment of wild-type heart
explants with CsA but proceeded normally in explantsdocardial cushions, chamber malformations, and septa-
tion defects (Stalmans et al., 2003), whereas lowering from embryos, lacking Cnb1 or NFATc1 in the endocar-
dium. Furthermore, triple mutant embryos, lackingVEGF levels at E9.5 by hyperglycemia or with a soluble
Flt1 chimeric protein (sFlt1) prevents EMT (Enciso et al., NFATc2/c3/c4, had cushion defects with a hypocellular
cardiac jelly. Though expression of NFATc2, c3, and c42003). Amplification of Flk1 signaling by semaphorin-6D/
plexin-A1 also regulates endocardial cushion formation. in the myocardium remains to be determined, the au-
thors suggest that myocardium-derived NFATc2, c3,These findings thus suggest that some VEGF expression
is required for endocardial cells to undergo EMT. How- and c4 cooperate in instructing the endocardium to un-
dergo EMT at E9.5. Evidence for a role of calcineurinever, at E10.5, when EMT reaches completion, myocar-
dial VEGF levels in the atrioventricular canal are elevated signaling in the endocardium was provided by findings
that endocardial loss of Cnb1 did not prevent EMT butby 5- to 10-fold (Dor et al., 2001, 2003; Miquerol et al.,
2000), raising the question of whether high VEGF levels impaired subsequent valve elongation—similar to
NFATc1 null embryos (de la Pompa et al., 1998). More-terminate EMT. Indeed, when myocardial VEGF levels
are “artificially” elevated via gene targeting, conditional over, endocardial expression of a NFATc1 transgene
restored valve formation in NFATc1 null embryos—allsite-specific overexpression, hypoxia, or supplementa-
tion at E9.5 just prior to EMT, heart valve formation is indicating that the endocardium provides critical signals
for valve elongation, under CnB/NFATc1 control. By us-disrupted (Dor et al., 2001, 2003; Miquerol et al., 2000).
Thus, low VEGF levels at E9.5 are required for EMT, ing CsA to pharmacologically knock down calcineurin,
they further showed that NFATc1 within the endocardialwhile high VEGF levels at E10.5 suppress this process.
In a series of elegant studies in mice and zebrafish, field functions in a precise developmental time window.
Another novel finding is that the authors identifiedChang et al. further unraveled the distinct roles of the
NFATc family members and calcineurin signaling in VEGF as a downstream signal of myocardium-derived
NFATs. Chang et al. demonstrate that myocardial VEGFvalve formation (Chang et al., 2004). Together, these
experiments suggest a model whereby spatial fields of levels in mice lacking NFATc2/c3/c4 or treated with CsA
were upregulated prematurely at the onset of EMTCnB/NFATc signaling, first in the myocardium and there-
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Maity, S., Kneer, P., von der Ohe, M., Swillen, A., Maes, C., et al.(Chang et al., 2004). As high VEGF levels at E9.5 inhibit
(2003). Nat. Med. 9, 173–182.EMT, they concluded that the elevated myocardial VEGF
levels blocked EMT in these triple mutant embryos. Nor-
malizing myocardial VEGF levels in the CsA-treated em-
bryos by administering sFlt1 restored valve develop-
ment. Thus, by preventing excessive upregulation of
VEGF to levels that would otherwise block EMT, myocar-
dium-derived NFATs allow EMT to proceed.
In their model (Figure 7G in Chang et al., [2004]), Chang
et al. suggest that NFATc2, c3, and c4 suppress myocar-
dial VEGF expression within but not outside the field
of valve formation. Others documented, however, that
myocardial levels are uniform within and outside this
field (Dor et al., 2001, 2003; Miquerol et al., 2000). An-
other outstanding issue is that Chang et al. observed
that treatment of wild-type E9.5 heart explants with sFlt1
enhanced EMT, while Enciso et al. reported that a higher
dose (than the one used by Chang) of sFlt1 blocked
EMT in wild-type heart explants (Enciso et al., 2003). It
remains to be explored whether the higher sFlt1 levels
blocked all VEGF signaling and thereby eliminated the
low “threshold” VEGF levels necessary for EMT, whereas
the lower sFlt1 levels removed only some of the excess
“inhibitory” VEGF and thereby enhanced EMT.
Now that a distinct role for the various NFATs in valve
formation is established, additional questions as to how
they function can be addressed. For instance, which
other NFAT partners are involved, which signals regulate
calcineurin/NFAT, and which downstream targets are
affected? The challenge for the future will be to integrate
the calcineurin/NFAT pathway together with preexisting
molecules, known to modulate valve formation, into a
unifying model of EMT and valve maturation.
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